Ophthalmology Therapeutics: Does current pipeline innovation hold the potential to affect the future ophthalmology market?

This Frontier Pharma: Ophthalmology Therapeutics assesses first-in-class innovation in the ophthalmology pipeline, highlighting key trends in the distribution of these products.

Pune, India - March 14, 2018 /MarketersMedia/ —

The pipeline is varied in terms of molecular targets and molecule types. Products acting on the immune system and neurotransmitter signaling are the most prevalent, but no single target dominates by any clear margin. There are a total of 194 first-in class pipeline products in development for ophthalmologic indications 38% of the 512 pipeline products for which there is a disclosed molecular target. Encompassing gene therapies, slowing of the visual cycle and antisense therapies, the pipeline appears robust and has huge potential to strengthen treatment options for ophthalmological disorders.

Access Report Details at: https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs

Reasons To Buy
• Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.
• Visualize the composition of the ophthalmological disorders market in terms of dominant molecule types and targets, and understand the current unmet needs and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
• Analyze the ophthalmological disorders pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating ophthalmological disorders to overcome the overwhelming level of unmet need.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
• Identify commercial opportunities in the ophthalmological disorders deals landscape by analyzing trends in licensing and co-development deals, and a curated list of ophthalmological disorder therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Get this report at: https://www.themarketreports.com/report/buy-now/935550

In the past the ophthalmological disorders therapy area has suffered from a lack of full understanding of the pathophysiology and underlying mechanisms of the diseases. However, as this knowledge has improved vastly in recent years, potential targets have been identified for treatment. As well as the main disorders previously mentioned, there is also interest in developing treatments for indications such as allergic conjunctivitis and retinitis pigmentosa. The approval of a gene therapy for retinitis pigmentosa is indicative of this progress, and represents the first gene therapy approved for an inherited condition by the FDA.

Inquire for more details at: https://www.themarketreports.com/report/ask-your-query/935550

Contact Info:
Name: Shirish Gupta
Email: sales@themarketreports.com
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL: https://marketersmedia.com/ophthalmology-therapeutics-does-current-pipeline-innovation-hold-the-potential-to-affect-the-future-ophthalmology-market/314326

For more information, please visit https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs%20%20

Source: MarketersMedia

Release ID: 314326

Latest News

Zuckerberg asked to testify in UK; data firm's CEO suspended

Mar 20, 2018

LONDON — A British parliamentary committee on Tuesday summoned Facebook CEO Mark Zuckerberg to answer questions as authorities stepped up efforts to determine if the personal data of social-media users has been used improperly to influence elections. The request comes amid allegations that a data-mining firm based in the U.K. used information from more than 50 million Facebook accounts to help Donald Trump win the 2016 presidential election. The company, Cambridge Analytica, has denied wrongdoing. However, the firm's board of directions announced Tuesday evening that it had suspended CEO Alexander Nix pending an independent investigation of his actions. Nix made...

The Latest: Cambridge Analytica suspends CEO pending probe

Mar 20, 2018

LONDON — The Latest on the alleged use of personal Facebook data by political consulting firm Cambridge Analytica (all times local): 7:05 p.m. The board of Cambridge Analytica says it has suspended CEO Alexander Nix pending a full independent investigation of his actions. The board cited comments Nix made to an undercover reporter for Britain's Channel 4 News and other allegations of wrongdoing for its action Tuesday. It said his comments "do not represent the values or operations of the firm and his suspension reflects the seriousness with which we view the violation." The board said in an announcement posted...

Spring-themed cake for Prince Harry, Meghan's spring wedding

Mar 20, 2018

LONDON — Lemon, elderflower, fresh flower decorations: The cake for Prince Harry and Meghan Markle's May wedding will be appropriately spring-themed. Kensington Palace said Tuesday the royal wedding cake will be a lemon elderflower concoction incorporating "the bright flavors of spring." It'll be covered with buttercream, and adorned with fresh flowers. Look for a hint of California too — the designated pastry chef Claire Ptak was raised in California and worked as a pastry chef under the celebrated Alice Waters at Chez Panisse in Berkeley. Ptak now runs Violet Bakery in London. The palace says the couple are "very much...

Eddie Redmayne announces birth of second child, a boy

Mar 20, 2018

LONDON — Oscar winner Eddie Redmayne and his wife have announced the birth of their second child, a boy. Luke Richard Bagshawe Redmayne was born March 10. He joins his 21-month-old sister Iris Mary. The 36-year-old in February told ABC's "Live with Kelly and Ryan" that he and his wife, Hannah, did not know the sex of their babies before birth. Redmayne won an Oscar for portraying Stephen Hawking in the 2014 film "The Theory of Everything." He also appeared in the 2016 Harry Potter prequel "Fantastic Beasts and Where to Find Them."

At least 13 hurt after car rams into nightclub in Britain

Mar 20, 2018

LONDON — British police say a man who had been kicked out of a nightclub rammed his car into revelers on a dance floor, injuring at least 13 people. The Kent Police force says the 21-year-old has been arrested on suspicion of attempted murder over Saturday's crash in Gravesend, 30 miles (48 kilometers) southeast of London. Police say they are not treating the incident as terrorism. Footage posted on social media showed a large car on a dance floor inside a marquee tent at Blake's nightclub. On Facebook, the club thanked "the heroic actions of our door team and guests...

Sign up now!